<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Thrombolytic therapy is likely to be effective in some patients with <z:hpo ids='HP_0001297'>stroke</z:hpo>, but further improvements may require combination treatment with neuroprotective agents that can be given rapidly with relative safety </plain></SENT>
<SENT sid="1" pm="."><plain>We tested the effects of tissue plasminogen activator (t-PA) with the <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> <z:chebi fb="68" ids="48706">antagonist</z:chebi> MK-801 or the <z:chebi fb="1" ids="38215">calcium channel blocker</z:chebi> nimodipine in an embolic <z:hpo ids='HP_0001297'>stroke</z:hpo> model </plain></SENT>
<SENT sid="2" pm="."><plain>We found that MK-801, followed by t-PA, was more effective than t-PA alone in reducing neurologic damage </plain></SENT>
<SENT sid="3" pm="."><plain>Nimodipine plus t-PA was not better than t-PA alone </plain></SENT>
<SENT sid="4" pm="."><plain>Combined <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> <z:chebi fb="68" ids="48706">antagonist</z:chebi> and thrombolytic therapy may provide increased efficacy and safety for <z:hpo ids='HP_0001297'>stroke</z:hpo> treatment </plain></SENT>
</text></document>